Article | Received 3 April 2026; Revised 27 August 2026; Accepted 23 September 2026; Published 28 September 2026
https://doi.org/10.55092/exrna20260014

Supplementary data

Circulating extracellular vesicle miRNAs for distinguishing prostate cancer and benign prostatic hyperplasia

Ting Ding[1,2], Xin Zhang[3] and Lijuan Yu[3,4,*]

[1] Department of Laboratory Medicine, The Second Hospital Affiliated to Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an, China
[2] Department of Laboratory Medicine, Xijing Hospital, Fourth Military Medical University (Air Force Medical University), Xi'an China
[3] Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single-cell and Extracellular Vesicles, Nanfang Hospital, Southern Medical University, Guangzhou, China
[4] Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

* Correspondence author; E-mail: ylj185@163.com.

Supplementary figures



Figure S1. The potential of PSA in differentiating prostate conditions. **(a)** The expression levels of PSA in BPH and PCa, data were analyzed using Mann–Whitney U test; **(b)** ROC curve for PSA in distinguishing between BPH and PCa, AUC = 0.682 (95% CI: 0.4992–0.8655).



Figure S2. The potential of three miRNAs in differentiating prostate conditions. **(a)** The expression levels of miR-148a-3p in different groups (BPH *vs.* localized PCa *vs.* bone metastatic PCa); **(b)** The expression levels of miR-375 in different groups; **(c)** The expression levels of miR-92a-1-5p in different groups; **(d)** The ROC curve of miR-375 in differentiating bone metastatic PCa from BPH, AUC = 0.736 (95% CI: 0.5668–0.9057). **(a–c)** Data were analyzed using Kruskal–Wallis test.